River blindness drug, Moxidectin, receives FDA approval
by Press Release from Outbreak News Today on (#3SAJ3)
Medicines Development for Global Health (MDGH) and the World Health Organisation Special Programme for Research and Training in Tropical Diseases (TDR) announced today that the United States (U.S.) Food and Drug Administration (FDA) approved moxidectin 8 mg oral for the treatment of river blindness (onchocerciasis) in patients aged 12 years and older. The FDA has also awarded MDGH ["]
The post River blindness drug, Moxidectin, receives FDA approval appeared first on Outbreak News Today.